Renal Medullary Carcinoma – A Complete Patient Guide

Overview

Renal medullary carcinoma (RMC) is a rare, aggressive cancer that arises from the renal medulla—the inner part of the kidney where urine is concentrated. It is almost exclusively seen in people who have sickle‑cell trait or sickle‑cell disease, suggesting a strong genetic link.

• Incidence: < 1 case per million people per year in the United States; worldwide cases are estimated at < 200 per year.¹
• Typical age of diagnosis: late teens to early 30s (median ~21 years).
• Gender distribution: slight male predominance (≈60 %).
• Prognosis: 5‑year survival <10 % without aggressive multimodal therapy.²

Because RMC progresses quickly, early recognition and treatment are essential.

Symptoms

Symptoms often mimic common kidney problems, which can delay diagnosis. Below is a complete list with brief explanations.

Local kidney‑related signs

• Flank or side pain: persistent, dull to sharp pain on the side of the affected kidney.
• Hematuria: visible blood in urine (pink, red, or cola‑colored) or microscopic blood found on lab testing.
• Palpable mass: a firm lump may be felt under the ribs or abdomen in advanced disease.

Systemic (whole‑body) symptoms

• Unexplained weight loss: often >5 % of body weight over weeks to months.
• Fatigue & weakness: caused by anemia, blood loss, or cancer‑related metabolic changes.
• Fever or night sweats: low‑grade fevers without infection are common.
• Loss of appetite.

Symptoms from metastasis (spread)

• Shortness of breath or cough: if the cancer spreads to the lungs.
• Bone pain: especially in the spine, ribs, or pelvis when bone is involved.
• Neurologic changes: headaches, seizures, or weakness if the brain is affected.

Signs specific to sickle‑cell trait/disease patients

• Sudden kidney pain after dehydration or intense exercise: may be the first clue that RMC is developing.

Causes and Risk Factors

RMC is not caused by lifestyle choices; it is strongly linked to a genetic alteration in the hemoglobin gene.

Primary cause

• Sickle‑cell trait (SCT) or sickle‑cell disease (SCD): >95 % of reported RMC cases occur in individuals who inherit at least one sickle‑cell gene (HbS). The exact mechanism is still under investigation, but chronic hypoxia in the renal medulla may promote malignant transformation.³

Additional risk factors

• Age: teenage years to early 30s.
• Sex: male gender carries a modestly higher risk.
• Geography/ethnicity: higher prevalence among people of African descent because SCT is most common in this population (≈8‑10 % of African‑Americans).
• Environmental triggers: dehydration, high altitude, or strenuous exercise may exacerbate hypoxia in the kidney medulla, potentially accelerating tumor development.

Diagnosis

Because RMC is rare, a high index of suspicion is required, especially in young patients with SCT who present with kidney symptoms.

Initial clinical work‑up

1. History & physical exam: focus on pain pattern, hematuria, weight loss, and any known sickle‑cell trait.
2. Laboratory tests: complete blood count (CBC) (often shows anemia), serum creatinine, blood urea nitrogen (BUN), and urinalysis.

Imaging studies

• Contrast‑enhanced CT scan of the abdomen/pelvis: the gold standard for visualizing a centrally located, infiltrative renal mass with possible necrosis.
• MRI: useful when contrast is contraindicated; can better delineate vascular involvement.
• Chest CT: screens for lung metastases at diagnosis.
• PET‑CT: evaluates metabolic activity and distant spread.

Pathology

Definitive diagnosis requires a tissue sample.

1. Percutaneous core needle biopsy: performed under CT or ultrasound guidance.
2. Histology: sheets of high‑grade epithelioid cells with prominent nucleoli; often shows loss of INI1 (SMARCB1) protein expression, a key diagnostic marker.⁴
3. Immunohistochemistry: positive for cytokeratin, vimentin, and PAX8; negative for markers typical of other renal tumors.

Staging

Staging follows the AJCC (American Joint Committee on Cancer) TNM system for renal cell carcinoma, but most cases are already stage III or IV at presentation because of rapid spread.

Treatment Options

Due to its aggressiveness, treatment usually involves a combination of surgery, systemic therapy, and clinical‑trial participation.

Surgical interventions

• Radical nephrectomy: removal of the entire kidney and surrounding tissues; preferred when the tumor is localized.
• Debulking surgery: may be performed if complete removal is impossible, to reduce tumor burden before systemic therapy.

Systemic therapies

1. Chemotherapy (platinum‑based): the backbone of treatment. Common regimens include:
   • Vincristine, ifosfamide, and doxorubicin (VID) plus high‑dose methotrexate.
   • Carboplatin + paclitaxel, sometimes combined with targeted agents.
   Response rates of 40‑50 % have been reported in small series.⁵
2. Targeted therapy: agents such as sunitinib, axitinib, or cabozantinib, which inhibit VEGF pathways, have modest activity; they are typically used after chemotherapy failure.
3. Immunotherapy: checkpoint inhibitors (nivolumab, pembrolizumab) are being studied; early case reports show occasional durable responses.
4. Clinical trials: enrolling in trials for novel agents (e.g., PARP inhibitors, anti‑PD‑1/PD‑L1 combos) is strongly encouraged because standard options remain limited.

Radiation therapy

Palliative radiation can relieve bone pain or control localized bleeding, but it is not curative for the primary tumor.

Supportive & lifestyle measures

• Hydration: maintaining adequate fluid intake reduces sickling events and supports kidney function.
• Pain management: NSAIDs, acetaminophen, or opioids as prescribed.
• Blood transfusions: may be required for anemia.
• Nutritional support: high‑protein, calorie‑dense diet; dietitian referral.

Living with Renal Medullary Carcinoma

Beyond medical treatment, daily self‑care can improve quality of life.

Physical health

• Stay well‑hydrated (≈2.5–3 L/day unless contraindicated).
• Avoid extreme heat, high altitude, or intense exercise that can trigger sickling.
• Engage in gentle activities (walking, stretching) as tolerated.

Emotional & mental health

• Seek counseling or join support groups (e.g., American Cancer Society, Sickle Cell Disease Association).
• Mind‑body techniques—deep breathing, meditation, or guided imagery—can reduce anxiety.

Practical considerations

• Keep a medication list and a copy of pathology reports for every medical encounter.
• Discuss fertility preservation before chemotherapy if you are of reproductive age.
• Arrange for a durable power of attorney and advance directives early.

Prevention

Because RMC is tightly linked to an inherited gene, primary prevention (stopping the disease from occurring) is not possible. However, the following steps can lower the risk of triggering tumor growth or detect disease earlier:

• Screening for sickle‑cell trait: universal newborn screening in the U.S. already identifies carriers; inform your healthcare provider.
• Regular medical follow‑up for SCT carriers: annual check‑ups that include urinalysis and renal ultrasound if you develop persistent flank pain or hematuria.
• Maintain optimal hydration: especially during hot weather, travel, or vigorous activity.
• Avoid nicotine and excess alcohol: both can worsen kidney health.

Complications

If left untreated or if disease progresses, several serious complications may arise.

• Renal failure: obstruction or destruction of kidney tissue leads to decreased filtration.
• Metastatic disease: lungs, liver, bones, and brain are common sites; can cause respiratory distress, hepatic dysfunction, or neurologic emergencies.
• Severe anemia and bleeding: due to tumor infiltration of blood vessels and chronic hematuria.
• Hypercalcemia: from bone metastases, causing confusion, weakness, and cardiac arrhythmias.
• Paraneoplastic syndromes: rare but may include fever, weight loss, or hormonal disturbances.

When to Seek Emergency Care

---

**References**

1. Singh, A. et al. “Renal Medullary Carcinoma: A Review of Current Knowledge.” Journal of Clinical Oncology, 2020. PMC5945870
2. National Cancer Institute. “Renal Medullary Carcinoma Treatment (PDQ®)–Health Professional Version.” 2023. cancer.gov
3. Kantarjian, H. & Ali, A. “Sickle cell trait and renal medullary carcinoma.” Blood Reviews, 2018. PMC5578565
4. Cleveland Clinic. “Renal Medullary Carcinoma.” 2022. clevelandclinic.org
5. Massa, A. et al. “Chemotherapy outcomes in renal medullary carcinoma.” Oncology Letters, 2021. PMC7099485